GlassScriptPhysician profile
Makensey Durrant
NPI 1063029486
$7,563.99
in general payments reported to CMS, 2019-2025
37 companies · $4,585 in 2025
The $4,585 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $148 · 2023: $1,523 · 2024: $1,199 · 2025: $4,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,164 · Travel and Lodging: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,164.14 |
| Travel and Lodging | $1,142.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,980.76 | 2024-2025 | Infinity, Proclaim, Freestyle Libre 3 |
| Abbvie INC. | $1,033.68 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $527.90 | 2025 | Ultomiris |
| Idorsia Pharmaceuticals US INC | $519.05 | 2023 | Quviviq |
| Lilly USA, LLC | $461.42 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $280.16 | 2025 | Symbravo |
| Pfizer INC. | $275.11 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $234.39 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $225.65 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Lundbeck LLC | $200.98 | 2025 | Vyepti |
| Biogen, INC. | $200.66 | 2025 | Vumerity, Tysabri |
| Emd Serono, INC. | $183.45 | 2025 | Mavenclad |
| Medtronic, INC. | $159.47 | 2025 | Percept PC Brainsense |
| Astellas Pharma US INC | $146.98 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $143.15 | 2023-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Makensey Durrant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.